When the time comes, you'll be judged for your actions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He's in your head too 24/7
Sleep well youngling
Didn't think the chickens would.
Weak
The doc consistently delivers
The FDA love working with him, that's why they granted Vivos a BDD for Radiogel.
World's worst parody account, you must try harder.
10K
"After providing addition information to the FDA on December 18, 2023, the FDA classified us as a Breakthrough device to our proposed Indication for Use."
Who's going to accuse the Doc of lying in a 10K about the FDA granting a BDD.
Let's see
Isopet is profitable
End of story
Notice how the story has changed
It used to be..."Isopet has never made a profit"
I show proof
Now "RDGL has too many overheads..."
Bunch of cowboys trying to spin a story.
In the upside world,
'investor' sees price going down and holds shares.
Funny you didn't get a chance to respond on the Isopet profitability..you're another fraud.
No wonder the prior management team never managed to get a BDD. They don't understand what is involved.
“We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness.
This is why Radiogel is one of only 20 odd Radiology devices EVER to be granted a BDD.
BDD
Ignore the nonsense posts. Someone can't read properly.
The FDA granted a breakthrough device designation for a reason.
They wouldn't do it on a whim, VIVOS have presented enough data to show that Radiogel is safe and effective.
“We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness.
This is why Radiogel is one of only 20 odd Radiology devices EVER to be granted a BDD.
Lol
The narrative the ex - employee is trying to create keeps failing
You love to see it
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.
Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness.
The poster would appear to be a moron.
BDD's do not get granted by the FDA on a whim.
If the poster wants to suggest that the BDD claim is false then they should probably take it up with the SEC rather than jerkying themselves off on message boards.
Yep still waiting for proof that Isopet was unprofitable in the last 1/4.
Ignore the fairy tales you hear.
why don't you highlight where in the last 10-K it shows isopet as unprofitable?
OK Einstein
Show us some evidence that Isopet isn't profitable.
1000% happening
Just not yet
Id imagine those ex employees would have some wild opinions.
Now imagine they started accusing the doc of lying about bring granted a BDD by the FDA. That would be extremely detrimental to RDGL investors, some of those investors might take it upon themselves to see if the ex employees have enough proof to back their claims up.
You can read?
If you can't see the correlation between the development and use of Isopet and the progession with Radiogel then I'm not sure you can be helped.
No one trusts the logic of someone with a 9 cent average that thinks the price is heading back to 5 cents and doesn't sell to rebut at their predicted price.
Defamation hasn't helped stop the train but I won't forget.
Tick tock
Thanks for the advice baggy #1
Defamation hasn't helped stop the train but I won't forget.
Tick tock
Still waiting - facts are facts.
Battelle's patents predominantly revolve around stimuli-sensitive gels and thermogelling polymers, which exhibit unique properties such as responsiveness to external stimuli and controlled release mechanisms. These patents, represented by patent numbers 6,296,831; 6,869,588; 7,033,571; 6,841,617; 2,327,325; 2,423,488; 6,660,247; and 7,033,571, span a range of applications in medical devices, drug delivery systems, and tissue engineering.
In contrast, Vivos Inc.'s patents showcase a more targeted approach, particularly in the field of medical treatments. Highlighted by patent numbers No.1811.191, US 16309:17/943,311, PCT/US22/4374, Serial Number 63436562, and Serial number 18/152,137, Vivos Inc.'s patents focus on specific innovations tailored to medical treatments. These include proprietary yttrium-90 phosphate particles for targeted therapeutic applications, optimized hydrogel components for medical applications, and innovative improvements in medical devices such as shipping containers and syringe shields.
Vivos Inc.'s have proprietary yttrium-90 phosphate particles, which are crucial for the effectiveness of Radiogel™. Without access to these particles and the corresponding production methods covered by Vivos Inc.'s patents, another company would be unable to replicate Radiogel™ directly from the Battelle patents alone.
Facts
"In our patent application (No.1811.191), we have developed a novel composition comprising yttrium-90 phosphate particles, which are specifically engineered for targeted therapeutic applications in the field of precision radiopharmaceutical therapy. These proprietary particles exhibit unique properties that make them ideal for use in products like Isopet® and Radiogel™, offering precise and effective delivery of therapeutic doses of radiation to targeted areas within the body. Our innovative yttrium-90 phosphate particles have been rigorously tested and found to demonstrate exceptional stability, biocompatibility, and therapeutic efficacy, making them a promising solution for the treatment of various medical conditions. With the issuance of this patent, we have established a solid foundation for extending patent protection for our proprietary particles, ensuring exclusivity in the production and utilization of these groundbreaking technologies for years to come."
It's quite a novel concept but from what I understand.
When you get to 2-4 weeks old you learn the ability to do more than one task at a time, and then through nature this amazing skill is retained throughout your life and even when you're a fully grown adult.
Then I also heard that it's possible to have a 'TEAM' (I think that's what it's called) so one person can work on one item, and then another can work on something separate.
Still waiting
H A H A H A - The Battelle license doesn't show how to make yttrium-90 phosphate particles
These particles are crucial for delivering therapeutic doses of radiation to specific areas within the body. Vivos Inc. holds patents covering the unique composition and production process of these yttrium-90 phosphate particles, giving them exclusive rights to manufacture and use them in products like Radiogel™.
Still waiting
H A H A H A - The Battelle license doesn't show how to make yttrium-90 phosphate particles
Battelle's patents predominantly revolve around stimuli-sensitive gels and thermogelling polymers, which exhibit unique properties such as responsiveness to external stimuli and controlled release mechanisms. These patents, represented by patent numbers 6,296,831; 6,869,588; 7,033,571; 6,841,617; 2,327,325; 2,423,488; 6,660,247; and 7,033,571, span a range of applications in medical devices, drug delivery systems, and tissue engineering.
In contrast, Vivos Inc.'s patents showcase a more targeted approach, particularly in the field of medical treatments. Highlighted by patent numbers No.1811.191, US 16309:17/943,311, PCT/US22/4374, Serial Number 63436562, and Serial number 18/152,137, Vivos Inc.'s patents focus on specific innovations tailored to medical treatments. These include proprietary yttrium-90 phosphate particles for targeted therapeutic applications, optimized hydrogel components for medical applications, and innovative improvements in medical devices such as shipping containers and syringe shields.
Vivos Inc.'s have proprietary yttrium-90 phosphate particles, which are crucial for the effectiveness of Radiogel™. Without access to these particles and the corresponding production methods covered by Vivos Inc.'s patents, another company would be unable to replicate Radiogel™ directly from the Battelle patents alone.
Prove me wrong - Battelle licences expired 2 years ago and no one can figure out how to make it.
The FDA granted the BDD for a reason.
Battelle's patents predominantly revolve around stimuli-sensitive gels and thermogelling polymers, which exhibit unique properties such as responsiveness to external stimuli and controlled release mechanisms. These patents, represented by patent numbers 6,296,831; 6,869,588; 7,033,571; 6,841,617; 2,327,325; 2,423,488; 6,660,247; and 7,033,571, span a range of applications in medical devices, drug delivery systems, and tissue engineering.
In contrast, Vivos Inc.'s patents showcase a more targeted approach, particularly in the field of medical treatments. Highlighted by patent numbers No.1811.191, US 16309:17/943,311, PCT/US22/4374, Serial Number 63436562, and Serial number 18/152,137, Vivos Inc.'s patents focus on specific innovations tailored to medical treatments. These include proprietary yttrium-90 phosphate particles for targeted therapeutic applications, optimized hydrogel components for medical applications, and innovative improvements in medical devices such as shipping containers and syringe shields.
Vivos Inc.'s have proprietary yttrium-90 phosphate particles, which are crucial for the effectiveness of Radiogel™. Without access to these particles and the corresponding production methods covered by Vivos Inc.'s patents, another company would be unable to replicate Radiogel™ directly from the Battelle patents alone.
I expect number 2
I'm surprised they didn't do this for the BDD though considering it's a material event but who knows
Defamation - when the times right I'll get them for the Doc.
AI is pretty cool
Sleep tight
24/7